Unanticipated increases in hepatic steatosis among human immunodeficiency virus patients receiving mineralocorticoid receptor antagonist eplerenone for non-alcoholic fatty liver disease.

ABSTRACT:

Background & aims

Non-alcoholic fatty liver disease is common in human immunodeficiency virus, but there are no approved therapies. The aim of this open-label proof-of-concept study was to determine the effect of the mineralocorticoid receptor antagonist eplerenone on hepatic fat in human immunodeficiency virus-infected patients with hepatic fat ≥5% by magnetic resonance spectroscopy.

Methods

Five subjects received eplerenone (25 mg daily × 1 week followed by 50 mg daily × 23 weeks). Laboratory tests were done at each visit, and the primary endpoint, change in hepatic fat content, was determined by MRI spectroscopy at baseline and week 24.

Results

The study was stopped early after observing unexpected significant increases in hepatic fat at week 24 (mean increase 13.0

SUBMITTER: Chaudhury CS 

PROVIDER: S-EPMC7939026 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature